FDA PCAC (the alternate tag) covers the same Pharmacy Compounding Advisory Committee work as #pcac. The committee votes on which substances belong on the 503A bulks list and where they sit (Category 1, 2, or 3), shaping research-peptide policy.
The most active 2026 thread: the FDA's removal of 12 peptides from Category 2 restrictions ahead of the July 23–24 PCAC meeting, plus the public-comment process around BPC-157, GHK-Cu, sermorelin, and other research peptides. The committee has also been the public-comment arena for the 19 injectable peptides covered in the FDA's 2023 effective ban.
Stories here cover meeting minutes, vote outcomes, and public comments. See #pcac for the canonical thread and #503a for the bulks list itself.
STAT News published an April 29 First Opinion piece arguing that the FDA's pending peptide reclassifications — driven by HHS Secretary RFK Jr.'s public enthusiasm for compounds like BPC-157 and GHK-Cu — risk reopening access to inadequately-tested compounds. The op-ed highlights specific safety concerns flagged in the FDA's original 2023 Category 2 designations: immunogenicity, impurities, and the absence of meaningful human clinical data. The piece is positioned as scientific-community pushback ahead of the July 23-24 PCAC meeting that will rule on seven peptides.
Empower Pharmacy published a detailed industry analysis of the FDA's April 16 announcement removing 12 peptides from Category 2 and convening the July 23-24 PCAC meeting. The piece walks through the practical implications for compounding pharmacies, distinguishes Category 2 removal from Section 503A Bulk Drug Substances List inclusion, and emphasizes the gap between regulatory action and clinical access — physicians and patients are pressuring compounders to prepare peptides legally restricted only weeks ago.
An ABC News-syndicated piece featuring emergency physician and medical toxicologist Dr. Stephanie Widmer ran across ABC affiliates including ABC7 San Francisco, ABC11 Raleigh-Durham, ABC7 Los Angeles, ABC7 Chicago, and ABC13 Houston this week. The piece flagged falsified peptide products tested at arsenic levels up to 10× the toxicity limit for injectables, lead contamination, purity ranging from 5–75%, and documented mislabeling. Cited safety concerns include cardiovascular strain, insulin resistance, psychiatric instability, and blood clots. The breadth of the broadcast parallels FOX's syndicated explainer earlier in the week.